J. Goldman & CO LP Curis Inc Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.94 - $8.85 $187,386 - $238,958	-27,001 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $1.11 Million - $2.42 Million	-148,505 Reduced 84.62%	27,001 $218,000
Q1 2021 May 17, 2021	SELL	$8.78 - $12.8 $834,846 - $1.22 Million	-95,085 Reduced 35.14%	175,506 $1.99 Million
Q4 2020 Feb 16, 2021	SELL	$1.08 - $8.2 $254,727 - $1.93 Million	-235,859 Reduced 46.57%	270,591 $2.22 Million
Q3 2020 Nov 16, 2020	BUY	$0.95 - $1.42 $481,127 - $719,159	506,450 New	506,450 $593,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.